PREDIMED: EVOO Reduced Atrial Fibrillation Risk by 38%

Atrial fibrillation is the most common sustained cardiac arrhythmia and a leading risk factor for stroke, yet primary prevention strategies have remained elusive. In 2014, Martinez-Gonzalez and colleagues published a PREDIMED sub-analysis in Circulation reporting that a Mediterranean diet supplemented with extra virgin olive oil reduced incident atrial fibrillation by 38% in a high-risk cohort of 6,705 adults.

Why This Study Matters

Most cardiovascular trials measure heart attack and stroke. Atrial fibrillation, despite affecting tens of millions of adults worldwide, has historically lacked a proven lifestyle intervention for primary prevention. Drug treatments target rate or rhythm after the arrhythmia develops -- they do not stop it from appearing in the first place.

PREDIMED (Prevencion con Dieta Mediterranea) was the largest randomized nutrition trial ever conducted in cardiovascular medicine. Its main 2013 publication showed that a Mediterranean diet supplemented with extra virgin olive oil or mixed nuts reduced the composite of stroke, myocardial infarction, and cardiovascular death by about 30%. The Martinez-Gonzalez 2014 analysis took a different question to the same dataset: did the diet also prevent atrial fibrillation?

That question matters because atrial fibrillation shares mechanistic ground with cardiovascular disease -- oxidative stress in atrial tissue, endothelial dysfunction, low-grade inflammation. If a diet rich in olive polyphenols modulates those pathways, it should plausibly affect arrhythmia incidence too. PREDIMED was the first randomized trial large enough and long enough to test that.

How It Was Designed

PREDIMED randomized 7,447 participants aged 55 to 80 with no prior cardiovascular disease but at high cardiovascular risk (either type 2 diabetes or at least three major risk factors such as smoking, hypertension, elevated LDL, low HDL, overweight, or family history of premature CHD). After excluding 742 participants with prevalent atrial fibrillation at baseline, the AFib analysis included 6,705 individuals.

Participants were randomly assigned to one of three diets: a Mediterranean diet supplemented with at least one liter per week of extra virgin olive oil, a Mediterranean diet supplemented with 30 g/day of mixed nuts, or a control diet of advice to reduce dietary fat. Compliance was verified with biomarkers -- urinary hydroxytyrosol for the EVOO group and plasma alpha-linolenic acid for the nut group.

Incident atrial fibrillation was adjudicated by a blinded events committee using medical records and electrocardiograms. Median follow-up was 4.7 years. The primary analysis used Cox proportional hazards models adjusted for age, sex, recruitment center, and other cardiovascular risk factors.

What They Found

Across 4.7 years, 246 new cases of atrial fibrillation were adjudicated -- 72 in the EVOO arm, 82 in the nuts arm, and 92 in the control arm.

Diet Arm	New AFib Cases	HR (95% CI)	Risk Reduction	Significant?
MedDiet + EVOO	72 / 2,231	0.62 (0.45 to 0.85)	38% lower	Yes
MedDiet + Nuts	82 / 2,229	0.89 (0.65 to 1.20)	11% lower	No
Low-fat Control	92 / 2,245	1.00 (reference)	--	--

Green indicates a statistically significant reduction in risk versus the low-fat control. HR values below 1.0 indicate lower risk; the confidence interval must not cross 1.0 to reach statistical significance.

Reading the Results

EVOO showed a clear, statistically significant effect. A hazard ratio of 0.62 corresponds to a 38% lower risk of developing atrial fibrillation in the EVOO arm compared with the low-fat control. The 95% confidence interval (0.45 to 0.85) is comfortably below 1.0, meaning the association is unlikely to be due to chance.

The nut arm did not reach significance. The point estimate of 0.89 suggests a modest 11% reduction, but the confidence interval (0.65 to 1.20) crosses 1.0. The trial cannot distinguish that result from no effect. This divergence is what makes the EVOO finding biologically interesting -- both arms followed the same Mediterranean dietary pattern, but only the polyphenol-rich olive oil arm prevented arrhythmia. The active ingredient appears to be in the oil, not the diet pattern alone.

The mechanism is plausible. Atrial fibrillation is driven in part by structural and electrical remodeling of atrial tissue, processes accelerated by oxidative stress and inflammation. Olive oil polyphenols -- hydroxytyrosol and oleuropein chief among them -- have demonstrated anti-inflammatory and antioxidant effects in both animal models and human studies. Reduced oxidative damage to atrial myocytes is a leading candidate mechanism for the effect observed here.

What Didn't Change

This is a post hoc analysis of a trial that was not originally designed to test atrial fibrillation as a primary endpoint. The authors are explicit about this limitation in the paper. While the result is statistically significant and the trial was randomized, hypotheses generated from secondary analyses generally require independent replication before being treated as definitive.

The mixed-nuts arm did not show a significant benefit, despite following the same overall Mediterranean diet pattern. This either means polyphenols specifically (not the broader diet) drive the effect, or that the nut intervention was simply underpowered for AFib. The study cannot distinguish between those interpretations.

PREDIMED was conducted in a Spanish population at high cardiovascular risk. Whether the same effect size applies to lower-risk populations, younger adults, or other dietary backgrounds is not directly addressed by this analysis.

Broader Context

The PREDIMED main trial remains the largest and most rigorous randomized test of a Mediterranean diet for cardiovascular prevention. Its main 2013 result -- a roughly 30% reduction in major cardiovascular events -- has been cited thousands of times and is referenced in major dietary guidelines. The 2014 AFib sub-analysis extends that work into arrhythmia prevention, a domain where pharmacological options are limited and side-effect burdens are high.

In 2011, the European Food Safety Authority authorized a health claim for olive oil polyphenols and the protection of blood lipids from oxidative damage, requiring at least 5 mg of hydroxytyrosol and its derivatives per 20 g of olive oil daily. That EFSA claim is one of the very few food-derived health claims the agency has approved, and it is mechanistically aligned with the AFib finding here: if polyphenols protect circulating lipids from oxidation, they plausibly also protect cardiac tissue from oxidative remodeling.

Subsequent observational and mechanistic work has reinforced the link between olive polyphenol intake and lower arrhythmia risk, though no large randomized trial has been designed specifically with AFib as a pre-specified primary endpoint. Until one is, the Martinez-Gonzalez 2014 result remains the strongest randomized evidence available.

Related Research

Continue exploring olive oil and polyphenol science:

• PREDIMED Republished: Mediterranean Diet + EVOO Cut Major CV Events by 30%
• Within PREDIMED: Higher EVOO Intake Linked to 48% Lower CV Mortality
• PREDIMED Outcome-Wide: EVOO and Multiple Cardiovascular Endpoints

Source: View the original study on PubMed

Olivea's Dosage

PREDIMED participants in the EVOO arm consumed at least 1 liter per week of extra virgin olive oil -- roughly four tablespoons per day. This was high-polyphenol oil supplied by the trial, not generic supermarket olive oil. Each Olivea capsule delivers the concentrated polyphenol content of olive oil in a single serving, and our extra virgin olive oil is third-party tested for polyphenol content. Our most recent certificate of analysis confirmed 23.5 mg of hydroxytyrosol per capsule.

According to PubMed, this study is indexed as PMID 24787471 (DOI: 10.1161/CIRCULATIONAHA.113.006921).

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.